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Our objective was to validate our estimates from our original model1 and re-evaluate the 
cost-effectiveness of Spleen Australia, the 
Australian post-splenectomy registry,2 using 
our original model with updated parameters 
based on advances in the literature and 
experience of the registry over the past 
decade.
The spleen has major roles in maintaining red 
cell integrity and immune function including 
antibody production and opsonisation of 
bacteria. Where splenic function is impaired; 
for example, functional hyposplenism, 
splenectomy or congenital asplenism, 
immune function is impaired. This puts the 
patient at a significant risk of infections 
including overwhelming post-splenectomy 
infection (OPSI), malaria, babesia, 
Capnocytophagia carnimorsus and Bordetella 
holmesii. 
OPSI is a syndrome of fulminant invasive 
infection that can lead to death within 
48 hours despite aggressive treatment. 
OPSI has a reported prevalence of 1 in 500 
splenectomised patients,3 with a mortality 
rate observed to range from 50% to 70%.4,5 
Although international guidelines vary 
slightly,2,6-8 overall they address three 
principles of prevention: immunisation, 
chemoprophylaxis and patient education. 
In Australia, Spleen Australia guidelines 
recommend the following management 
strategies:2
•	 Immunisation – Recommendations 
include initial and ongoing booster 
vaccination against Streptococcal 
pneumoniae, Neisseria meningitidis and 
Haemophilus influenzae type b (HiB), and 
annual administration of the influenza 
vaccination.
•	 Chemoprophylaxis – All patients 
are recommended daily penicillin or 
amoxicillin (or a macrolide if allergic) for 
at least three years after splenectomy, and 
life-long antibiotics if they are at high risk 
for infections (e.g. immunocompromised 
patients). Patients should also carry 
a supply of antibiotics (commonly, 
amoxicillin three grams) to use in an 
emergency in the case of severe illness. 
•	 Education – Patients and their family 
members should be informed about 
the risk of infections, the importance of 
immunisations and antibiotics, and the 
need to present early to medical services in 
the event of sudden severe illness. Patients 
should know to seek travel advice prior to 
travel and be aware of the infectious risk 
with animal bites. It is recommended that 
patients always carry a medical alert in 
the form of a bracelet or wallet-sized card 
in case they present with illness and an 
impaired state of consciousness. 
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Abstract
Objective: To validate our estimates from our original model and re-evaluate the cost-
effectiveness of Spleen Australia, the Australian post-splenectomy registry, using our original 
model with updated model parameters based on advances in the literature and experience of 
the registry over the past decade.
Methods: We revisited a decision model from 2005, comparing 1,000 hypothetical registered 
patients with asplenia or hyposplenism against 1,000 who were not registered, and updated 
the model parameters. The cost-effectiveness of the registry was evaluated from a healthcare 
perspective in terms of additional cost per case of overwhelming post-splenectomy infection 
(OPSI) avoided and as additional cost per life year gained. 
Results: Over a cohort lifetime the registry was associated with an additional cost of $125,724 
per case of OPSI avoided or $19,286 per life year gained. 
Conclusions: Despite our initial over-estimation of immunisation and chemoprophylaxis 
uptake and increases in unit costs, our re-evaluation confirmed use of the registry to be cost-
effective.
Implications for public health: Improved outcomes for patients with asplenia or hyposplenism 
can be achieved by a cost-effective registry. Additional research into effectiveness of 
interventions, OPSI prevalence associated with varying intervention use, and compliance rates 
over time after registration would provide improved accuracy of cost-effectiveness estimates. 
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A registry with a key role in improving 
education, early diagnosis and treatment 
of OPSI has been suggested to not only 
reduce rates of infection, but also reduce 
the mortality risk to 10%9 by improving the 
uptake of interventions.10 
The Spleen Australia registry was established 
in 2003 as the Victorian Spleen Registry and 
has since expanded to include Tasmania and 
Queensland. The primary role of the registry 
is to reduce the risk of OPSI. To achieve this, 
patients are contacted upon registration 
by phone and where possible in person. 
Registrants receive an education kit in the 
mail that contains brochures informing them 
of their risk of infections, the most recent 
registry newsletter, an alert card, a vaccine 
record card and a personal immunisation 
report. Annual newsletters are sent to 
registrants and their nominated medical 
practitioner(s). Registrants can also access 
their personal immunisation report via the 
Spleen Australia phone application. 
In 2005, our group performed a cost-
effectiveness analysis of the registry.1 At 
the time, the registry had been running for 
approximately two years with fewer than 
250 patients registered with the registry. This 
model estimated that, although the registry 
would not be cost-saving (as costs incurred 
in running the registry are more than those 
saved from reduced OPSI rates), in the long 
run (i.e. over the lifetime of the registered 
population) a registry-based approach was 
likely to prove cost-effective in terms of 
cases of OPSI avoided and life years gained. 
Uncertainty around model estimates revealed 
that these results were most sensitive to 
estimates of the rate of OPSI occurrence, 
the mortality rate following OPSI and the 
risk reduction generated by preventive 
interventions. Improving evidence available 
for these parameters would improve the 
certainty around future updates of this model.
Our original model highlighted the limited 
evidence in the field,1 and little has improved 
in the intervening decade. Two Australian 
studies indicated that we initially over-
estimated registry and non-registry model 
parameters.11,12 We assumed that registrants 
would have 100% uptake of interventions. A 
survey of Spleen Australia registrants found 
that 79% reported booster vaccination, 84% 
reported annual influenza vaccination and, 
among participants within their first two 
years since splenectomy, 83% reported taking 
antibiotics.11 A study among non-registered 
post-splenectomy patients in New South 
Wales revealed that, despite a high initial 
vaccination rate (93%), 12% of patients took 
up ongoing influenza vaccine and 40% used 
prophylactic antibiotics.12
In terms of outcomes, the number of invasive 
pneumococcal disease (IPD) cases in the 
asplenic population in Victoria in 2010–2015 
ranged from two to nine per annum (mean 
5.6).13 Where vaccination was known, 57% 
were fully vaccinated and 43% were not. A 
study in Victoria suggested that registration 
is associated with a reduction in vaccine-
preventable disease rates of 69%.14 The 
costs of treating a case of OPSI remains 
highly variable, with cases notified to Spleen 
Australia costing up to $280,000 (in 2014).
In 2016, we combined the registry 
experience to date and findings of the two 
recent Australian studies11,12 to update the 
parameters of our original model1 and assess 
implications for effectiveness and cost-
effectiveness estimates. 
Methods
We performed a cost-effectiveness analysis 
from a healthcare perspective using a 
decision tree model with Markov nodes 
comparing a cohort of 1,000 registry 
participants to a cohort of 1,000 people 
with asplenia or hyposplenism not covered 
by a registry.1 The Markov nodes are annual 
health states. Cohort age on entry was 
set to the mean age of patients registered 
at the time of initial model construction 
(48 years). The impact of the registry was 
assessed through uptake rates of vaccination, 
chemoprophylaxis and education, on 
outcomes of OPSI and mortality. Costs and 
outcomes were evaluated over the initial two 
years of registration (when costs are expected 
to be high) and the remaining lifetime of the 
cohort (approximately 60 years). All costs 
and outcomes that occur in the future are 
discounted at 5%, so the expression of costs 
and outcomes is in terms of their net present 
values. 
Similar to our original model, we chose 
to focus on OPSI as the primary outcome 
measure. The model was evaluated for two 
OPSI-related outcomes: the number of cases 
of OPSI prevented (the difference in number 
of cases of OPSI estimated for the cohort 
with and without a registry) and the number 
of years of life gained with (compared to 
without) a registry. This is directly related 
to the cases of OPSI prevented, as the only 
sources of mortality in the model cohorts are 
the background life expectancy (common 
across the two cohorts) and the mortality 
following OPSI. 
We updated our model parameters to reflect 
the newly available evidence (see Table 1).11,12 
There is no additional evidence on OPSI risk 
or the effectiveness of interventions (with 
or without a registry) on OPSI risk reduction. 
We retained the model parameters from 
the initial model for OPSI risk reduction 
with intervention, as the study performed 
by El Alfy et al.15 remains the best available 
estimate for reduction in OPSI risk with 
varying uptake of interventions to date  
(Table 1).
The original estimates of resources required 
for initial education remained valid and were 
updated to 2016 Australian dollars to reflect 
general inflation and current treatment 
recommendations (Table 1). All cost estimates 
were based on the costs experienced in the 
local hospital and costs experienced by the 
registry. The increased scale of operation 
of the registry (beyond expectations of 
the original model) has resulted in greater 
distribution of annual fixed administration 
costs ($250,000) distributed among 5,000 
participants ($50/participant). Conversely, 
vaccine costs have increased due to additions 
to the recommended vaccines. The cost 
of a treating a case of OPSI was based on 
local hospital cost data from known OPSI 
cases. The cost of treating a case of OPSI in 
hospital remains highly variable and available 
estimates remain within the original range, so 
we maintained the original estimate.
Results
Baseline estimates and associated ranges 
of uncertainty for each required category of 
model input are shown in Table 1. Cost-
effectiveness results are presented in Table 2. 
Costs and benefits of the registry are shown 
for both the first two years of implementation 
and over the lifetime of the cohort 
(approximately 60 years).
In the first two years, the additional cost of 
the registry was $211,077 per case of OPSI 
avoided or $284,846 per life year gained. 
After this initial registration period the cost-
effectiveness improves over time, such that 
over the cohort lifetime a post-splenectomy 
register is associated with an additional cost 
of $125,724 per case of OPSI avoided or 
$19,286 per life year gained. 
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Discussion
We now have 10 years of monitoring data 
for a vastly increased registry cohort that has 
allowed us to self-evaluate and validate the 
assumptions of the original model of cost-
effectiveness of the Spleen Australia registry. 
The most noticeable divergence between the 
2005 model and the lived experience of the 
Spleen Registry was in the scale of operation. 
The original model was based on a cohort of 
1,000 registered participants and included 
administrative costs based on an expected 
scale of 500 registry participants and an 
anticipated general administrative cost of 
$40,000 per annum. This scale was reached 
within a few years of the initial model. As of 
April 2018, there are now more than 7,890 
patients enrolled on the registry, with over 
1,000 new registrations each year. 
Our updated model estimates that use of 
a spleen registry generates 64 additional 
years of life for a cohort of 1,000 patients, at 
a cost of $19,286 per life year gained. There 
is greater distribution of administration 
costs with a larger registry cohort, leading 
to a lower administration cost of $50 per 
registrant. Due to increased vaccination 
costs (from general inflation and additions 
to the management recommendations) and 
reduced estimates of treatment uptake, the 
cost of preventing an OPSI case ($105,154 
to $125,724 per OPSI case avoided) and the 
cost per life year gained ($16,113 to $19,286 
per life year gained) has increased from our 
previous estimates, as shown in Table 2. 
Although the estimated rate of return has 
increased from $16,113 per life year gained 
to $19,286 per life year gained, the updated 
estimated rate of return remains within the 
range of commonly funded interventions in 
Australia (up to $60,000 per healthy life year 
gained).16 
There have been no studies comparing 
cost-effectiveness of Australian clinical 
registries, other than a report by the Australian 
Commission on Safety and Quality in Health 
Care that assessed the cost-effectiveness 
of five Australian clinical registries.17 This 
report concluded that these five clinical 
registries provided significant positive return 
on investment but declared that not every 
clinical registry that is established will be 
cost-effective. In our evaluation, we show that 
although using this registry is not cost-saving, 
it does appear to be cost-effective when 
viewed over a cohort lifetime and is associated 
with improved patient health benefits. 
Table 1: Outcomes and cost estimates in the initial model and updated model.
Initial Model (2005) Updated Model (2016)
Estimate Range Estimate Range
Uptake of interventions with registry: 100% 100% 84% 80–90%
Uptake rate in absence of registry:
 Vaccination
 Chemoprophylaxis
 Education
90%
67%
22%
80–90%
20–70%
10–60%
80%
40%
22%
70–90%
20–70%
10–60%
OPSI rate without intervention 0.5% 0.23–0.5% 0.5% 0.23–0.5%
OPSI risk reduction with intervention:
 Vaccination, chemoprophylaxis and education
 Vaccination and chemoprophylaxis
 Vaccination only
70%
60%
50%
50–84%
50–73%
50–56%
70%
60%
50%
50–84%
50–73%
50–56%
Mortality following OPSI 50% 20–70% 50% 20–70%
Unit cost of: 
 Vaccination on entry (all below plus HiB)
 Vaccination - influenza (annual)
 Vaccination - pneumococcal (every 5 years)
 Vaccination - meningococcal (every 5 years)
 Chemoprophylaxis (per year of antibiotics)
 Education on entry (nurse consultation)
 Education (annual communications)
 Registry administration costs per person
 Cost of OPSI case
$143
$30
$37
$30
$172
$38
$1
$80
$50,000
$71–$215
$14–$43
$19–$56
$15–$45
$86–$257
$19–$57
$0.5–$1.5
$40–$120
$27,014–$96,513
$425
$25
$200
$200
$200
$50
$1
$50
$50,000
$213–$638
$13–$38
$100–$300
$100–$300
$100–$300
$25–$50
$0.5–$1.5
$40–$120
$27,014–$96,513
Table 2: Cost effectiveness of registry in the initial 
model and updated model.
Initial Results 
(2005)
Updated Results 
(2016)
Cost effectiveness over lifetime perspective
OPSI cases 
avoided
12.5 cases 
(undiscounted 25.6)
9.9 cases 
(undiscounted 20.2)
Life years 
gained
81.8 years 
(undiscounted 242)
64.2 years 
(undiscounted 191)
Additional 
costs
$1,319,093 $1,239,544
$ (per OPSI 
case avoided)
$105,154 $125,724
$ (per life year 
gained)
$16,113 $19,286
Cost effectiveness over first two years
OPSI Cases 
Avoided
1.6 cases 1.2 cases
Life years 
gained
1.2 years 0.9 years
Additional 
Costs 
$239,036 $258,799
Cost (per OPSI 
Case avoided)
$152,611/OPSI $211,077/OPSI
Cost (per life 
year gained)
$205,911/year $284,846/year
We initially anticipated this service to be a 
state-wide registry and evaluated its cost-
effectiveness in this scale. In performing this 
re-evaluation, we realised that not only did we 
over-estimate compliance to interventions, 
but we also underestimated the scale and 
growth of the registry. However, despite 
inaccuracies in our initial modelling estimates, 
our results revealed that the initial model 
accurately predicted that the registry would 
be a cost-effective intervention.1 In addition, 
we chose OPSI as our primary outcome 
measure. Although OPSI is the most important 
infectious outcome, risk of other infectious 
outcomes including but not limited to malaria, 
Capnocytophagia carnimorsus and Bordetella 
holmesii are likely to be reduced with registry 
use. Thus, limiting our assessment to OPSI as 
the primary outcome is likely to have missed 
some benefits of the registry.
Although this re-evaluation has incorporated 
recent evidence and data, it also highlights 
the limited breadth and depth of the 
literature regarding OPSI risk reduction with 
varying intervention use and the efficacy 
of such interventions. Estimates of cost-
effectiveness remain most sensitive to the 
accuracy of these efficacy data. We also 
still have limited data on the proportion of 
patients with asplenia or hyposplenism who 
are not registered in Victoria, Tasmania and 
Queensland. Vaccine uptake rates appear 
higher among registered cohorts11 compared 
to non-registered cohorts,12 suggesting a 
mechanism for lower rates of preventable 
infections in those on the spleen registry.14 
Conclusions
Use of a registry appears to have a causal 
impact on increasing compliance rates to 
management interventions and reduction 
in adverse infectious outcomes. Our re-
evaluation finds that although the registry 
is not cost-saving, it does appear to be cost-
effective.
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Implications for public health
Practice recommendations
It is logical to expand the registry to host 
all states and territories within Australia 
to optimise uptake of preventive health 
interventions and thus infectious outcomes in 
patients with asplenia or hyposplenism, since 
many of the capital costs of development 
of intellectual property, online support 
systems and registry software are fixed. In 
addition, clinicians should actively register 
patients with asplenia or hyposplenism to 
the healthcare service to improve adherence 
to management and prevention of adverse 
infectious outcomes.
Research recommendations
Rates of compliance in registrants over time 
would provide better long-term estimates 
of effectiveness and cost-effectiveness. In 
addition, greater precision over estimates 
of OPSI prevalence with varying levels of 
uptake of preventive interventions, and the 
effectiveness of interventions – particularly 
the use of long-term chemoprophylaxis – 
would reduce uncertainty over estimates of 
registry effectiveness and cost-effectiveness.
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